Valeant Pharmaceuticals surprised the industry late last week when it upped its offer to acquire Allergan, the second such bid increase in a single week.
The Canadian company reportedly boosted its offer to $53 billion to acquire the Botox manufacturer. The offer stacks up at $72 a share, increased from last Wednesday’s offer of $58.30 a share.
In a statement from Valeant, the company said its increased offer is contingent upon Allergan responding promptly to the proposal so the two can launch negotiations.
Last month Allergan rejected a $46 billion offer from Valeant because it undervalued the company’s worth, Allergan said.
Full content: USA Today
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.